Succinic Acid

Succinic Acid

SCHEMBL3186231

O=C(O)CCC(=O)O.O=C1CCCCCCCCC1S

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.39
FFAR1 O14842 2/20 0.39
FFAR4 Q5NUL3 2/20 0.39
MCL1 Q07820 1/20 0.39
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA4 P22748 2/20 0.36
CA6 P23280 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
GAA P10253 1/20 0.35
FOLH1 Q04609 1/20 0.34
HTT P42858 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EPHX2 P34913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28983235 0.84 KMT2A (0.52) ALDH1A1KMT2AMCL1CA1CA2
Cyclopentane SCHEMBL8879018 0.84 KMT2A (0.52) ALDH1A1KMT2AMCL1CA1CA2
Cyclohexane SCHEMBL8879285 0.84 KMT2A (0.52) ALDH1A1KMT2AMCL1CA1CA2
SCHEMBL11657362 0.84 KMT2A (0.52) ALDH1A1KMT2AMCL1CA1CA2
SCHEMBL4989703 0.84 KMT2A (0.52) ALDH1A1KMT2AMCL1CA1CA2
SCHEMBL822982 0.84
SCHEMBL112763 0.84 KMT2A (0.52) ALDH1A1KMT2AMCL1CA1CA2
Methane SCHEMBL27674323 0.82 KMT2A (0.50) ALDH1A1KMT2AMCL1CA1CA2
SCHEMBL822956 0.82
Methane SCHEMBL8878704 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9987217-B2 Blackberry extract SYMRISE AG (DE) 2018-06-05 US disclosed
US-9706791-B2 Aroma particles SYMRISE AG (DE) 2017-07-18 US disclosed
US-20140127390-A1 AROMA PARTICLES SYMRISE AG (DE) 2014-05-08 US disclosed
US-8641945-B2 Method of preparing aroma particles SYMRISE AG (DE) 2014-02-04 US disclosed
US-20100007040-A1 Method of preparing aroma particles SYMRISE GMBH & CO. KG (DE) 2010-01-14 US disclosed
EP-1761271-B1 BLACKBERRY EXTRACT SYMRISE GMBH & CO KG (DE) 2008-12-03 EP disclosed
US-20080279791-A1 Use of Isoeugenol Methyl Ester as an Agent Against Bad Breath SYMRISE GMBH & CO. KG (DE) 2008-11-13 US disclosed
EP-1919284-A1 USE OF ISOEUGENOL METHYL ETHER AS AN AGENT AGAINST BAD BREATH Symrise GmbH & Co. KG (DE) 2008-05-14 EP disclosed
US-20080095719-A1 Blackberry Extract SYMRISE GMBH & CO. KG (DE) 2008-04-24 US disclosed
US-20080063610-A1 Use of Beta-Homocyclocitral as an Agent Against Bad Breath SYMRISE GMBH & CO. KG (DE) 2008-03-13 US disclosed
EP-1793795-A1 USE OF BETA-HOMOCYCLOCITRAL AS AN AGENT AGAINST BAD BREATH Symrise GmbH & Co. KG (DE) 2007-06-13 EP disclosed
EP-1761271-A1 BLACKBERRY EXTRACT Symrise GmbH & Co. KG (DE) 2007-03-14 EP disclosed
WO-2006032664-A1 USE OF ISOEUGENOL METHYL ETHER AS AN AGENT AGAINST BAD BREATH SYMRISE GMBH & CO. KG (DE) 2006-03-30 WO disclosed
WO-2006032667-A1 USE OF BETA-HOMOCYCLOCITRAL AS AN AGENT AGAINST BAD BREATH SYMRISE GMBH & CO. KG (DE) 2006-03-30 WO disclosed
WO-2005123101-A1 BLACKBERRY EXTRACT SYMRISE GMBH & CO. KG (DE) 2005-12-29 WO disclosed
US-20050220981-A1 Aroma particles SYMRISE AG (DE) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080063610-A1 Use of Beta-Homocyclocitral as an Agent Against Bad Breath BAD, BAX, BAK1 ALDH1A1 3908/4885KDM4E 4519/4885LMNA 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.